Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Intravenous remdesivir (RDV) is US Food and Drug Administration–approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS‐443902, and other metabolites. Alternative administration routes, including localized pulmonary delivery, can lo...
Alternative Titles
Full title
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_ab437c86ec334aa9a0a440c7bdc247ab
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_ab437c86ec334aa9a0a440c7bdc247ab
Other Identifiers
ISSN
1752-8054,1752-8062
E-ISSN
1752-8062
DOI
10.1111/cts.13627
